Thursday's Biggest Analyst Calls: Nvidia, Netflix, Amazon, Microsoft, Tesla, Meta, Campbell Soup & More|

Here are Thursday’s biggest calls on Wall Street:

Citi on Gilead Sciences
Citi initiated coverage on biotech company Gilead Sciences with a "buy" rating, citing a positive outlook on the company's HIV product line. They set a price target of $125 for Gilead, reflecting their optimism about its growth potential.

‍

Piper Sandler on Campbell Soup
Piper Sandler upgraded Campbell Soup from "neutral" to "overweight," noting an ideal buying opportunity due to positive long-term growth expectations, especially for Campbell's Rao’s brand. Improved retail sales and volume trends in the U.S., excluding newly acquired brands, support this stance. Despite these improvements, Campbell’s stock has dropped approximately 15% since mid-September, which Piper Sandler views as an attractive entry point for investors.

‍

UBS on Cogent Communications
UBS began coverage on Cogent Communications with a "buy" rating, noting the internet services company is poised for significant revenue growth. UBS set a price target of $102, expecting continued momentum in Cogent’s offerings.

‍

Oppenheimer on Nvidia
Oppenheimer reiterated its "buy" rating on Nvidia, emphasizing the company’s strong positioning in the AI sector, supported by its comprehensive AI hardware and software capabilities. With Nvidia’s earnings on the horizon, Oppenheimer raised its price target from $150 to $175, expressing confidence in the company’s outlook.

‍

Jefferies on Tesla
Jefferies maintained its "hold" rating on Tesla but raised its price target from $195 to $300. The firm suggested Tesla could leverage the recent 30% stock re-rating to raise equity, especially given market competition and deregulation trends. These conditions may open growth opportunities but also heighten the investment requirements for Tesla and other companies in the autonomous vehicle and robotics sectors.

‍

Bank of America on ArcelorMittal
Bank of America upgraded steel manufacturer ArcelorMittal from "neutral" to "buy," pointing to an attractive valuation. They highlighted ArcelorMittal’s dominant position across key markets such as automotive and construction, with a broad presence spanning Europe, Asia, Africa, and America.

‍

Morgan Stanley on Doximity
Morgan Stanley upgraded Doximity, an online network for medical professionals, from "underweight" to "equal weight." They believe consensus estimates for the company are too conservative, seeing signs of renewed momentum in Doximity’s business that could lead to upward revisions.

‍

Evercore ISI on Target
Ahead of Target’s upcoming earnings report, Evercore ISI issued a negative tactical call on the retailer, expecting a deceleration in sales trends. They see potential downside in Target's stock, forecasting it could dip to $140.

‍

KeyBanc on Papa John’s
KeyBanc downgraded Papa John’s from "overweight" to "sector weight," citing a slower-than-expected recovery in sales trends and store profitability. According to KeyBanc, this recovery may necessitate further reinvestment from Papa John’s and its franchisees.

‍

JPMorgan on Blueprint Medicines
JPMorgan initiated coverage on Blueprint Medicines with a "buy" rating, describing the biotech company as a valuable franchise that is not fully recognized by the market. They set a price target of $126 by December 2025, projecting robust future growth.

‍

Compass Point on BXP
Compass Point upgraded BXP, a real estate investment trust, from "neutral" to "buy." Citing an $88 price target, they argue that BXP’s office properties, especially those in Manhattan, are undervalued compared to similar peers. BXP’s solid balance sheet and access to debt markets enhance its investment appeal.

‍

Wells Fargo on Burlington
Wells Fargo reiterated its strong recommendation for Burlington, naming it a top pick before the retailer’s earnings release. They expect Burlington to report favorable results, driven by accelerating customer traffic.

‍

JPMorgan on Netflix
JPMorgan restated its "overweight" rating on Netflix, highlighting investor optimism around the company’s fourth-quarter content lineup. Confidence remains high that Netflix will meet its revenue and operating margin goals for 2025, along with delivering significant free cash flow growth.

‍

Barclays on American Airlines
Barclays upgraded American Airlines from "underweight" to "equal weight," anticipating an improvement in business travel and a favorable renegotiation of co-branded card agreements by 2025. They see these factors as potential drivers of future growth.

‍

Morgan Stanley on Meta
Morgan Stanley reaffirmed its "overweight" rating on Meta, highlighting the company as a significant beneficiary of AI advancements. Meta’s AI tools have rapidly gained traction, achieving usage levels comparable to other popular AI applications.

‍

Needham on Amazon
Needham raised its price target on Amazon from $210 to $250, maintaining a "buy" rating. Amazon's emphasis on customer-centric innovation and feedback-driven product development, which allows employees to quickly implement and scale ideas, supports this bullish outlook.

‍

JPMorgan on ResMed
While JPMorgan kept an "overweight" rating on ResMed, they placed the company on a negative catalyst watch due to several anticipated challenges. Notably, FDA approval for Eli Lilly's Zepbound for sleep apnea treatment and results from Novo Nordisk’s weight-loss drug trial could impact ResMed’s competitive positioning.

‍

Jefferies on Microsoft
Following a visit to Microsoft headquarters, Jefferies reiterated its "buy" rating on the tech giant. The firm believes Microsoft is poised to re-rate positively as it continues to execute on its strategic initiatives effectively.

‍

This snapshot of Wall Street calls provides a mix of bullish and cautious stances, reflecting analyst perspectives on opportunities and potential risks across various sectors.

‍